Loading company…
Shenzhen Enduring Biotech develops bispecific antibody therapies and biobetter medicines.
Founded in 2018 in Shenzhen, China, Shenzhen Enduring Biotech develops bispecific antibody therapeutics and biobetter medicines. Its programs include JY108 for autoimmune diseases and candidates for cancer immunotherapy and combination therapy. The company plans to advance JY108 toward an investigational new drug application, continue early research and build pilot facilities.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in